Kyntra Bio Inc. (KYNB)
KYNB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$5.87
-4.08% on the day
Market cap
$23.8M
Nano cap
Revenue · 2025
$6.4M
-78.3% on 2024
Net income · 2025
$183.5M
2848.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | KYNB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0000921299 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.4M |
| Net income | $183.5M |
| Operating income | -$45.9M |
| Net margin | 2848.6% |
| Operating margin | -712.7% |
| Revenue growth | -78.3% |
| Cash | $47.9M |
| Total assets | $119.6M |
| P/E (computed) | 0.1× |
| P/S (computed) | 3.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-02-24 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PBM | Psyence Biomedical Ltd. Common Shares | $4.55 | -4.01% | $24.2M |
| QNTM | Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $2.89 | +2.48% | $24.5M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $5.18 | -4.95% | $24.7M |
| TXMD | TherapeuticsMD Inc. | $1.96 | -2.97% | $22.7M |
| BYSI | BeyondSpring Inc. | $0.6067 | -1.43% | $24.9M |
| CNTX | Context Therapeutics Inc. | $0.2750 | -9.84% | $25.3M |
| MCRB | Seres Therapeutics Inc. | $2.53 | -5.60% | $25.4M |
| ATOS | Atossa Therapeutics Inc. | $2.56 | +7.17% | $25.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier